On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > BUSINESS
BUSINESS
- Shionogi’s Novel Antibacterial Shows Effectiveness in Urinary Tract Infection
January 13, 2017
- SBI Biotech Licenses Autoimmune Disease Med to Kyowa Kirin
January 13, 2017
- Takeda Invests US$125 Million in Maverick for T-Cell Therapy, Buyout Eyed
January 13, 2017
- AbbVie’s 8-Week Hep C Med Delivers High SVR12 Rate in Japanese
January 13, 2017
- Imigran AG to Get Off Strong Start: Aspen Japan
January 12, 2017
- Astellas Bows Out from Flu Vaccine Development Pact with UMN
January 11, 2017
- Daiichi Sankyo to Shutter Indian Research Subsidiary
January 11, 2017
- Plavix AG Now Has All Same Indications as Originator
January 11, 2017
- Daiichi Sankyo Gets Japan Rights to Kite’s CAR T-Cell Therapy
January 11, 2017
- Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO
January 11, 2017
- Teva Takeda Recalls Ciprofloxacin Generic
January 11, 2017
- Janssen, Fukushima Medical Univ. to Engage in Joint Research for ADHD Biomarkers
January 11, 2017
- Pharma Leaders Urge Govt to Lend Ear to Industry Opinions for Pricing Revamp
January 10, 2017
- Otsuka Files Schizophrenia Med Brexpiprazole in Japan
January 10, 2017
- Takeda, US Biotech Strike Deal on Celiac Disease Treatment
January 10, 2017
- Opdivo Gastric Cancer Filing Casts Cloud on Keytruda’s Sakigake Status
January 10, 2017
- Takeda to Buy US Oncology Firm Ariad
January 10, 2017
- Eisai Expands Deal with Arena, Gets All Global Rights to Belviq
January 6, 2017
- Kyowa Kirin’s KRN23 Filed in Europe for X-Linked Hypophosphatemia
January 6, 2017
- SSP Now under Sanofi Group in Japan after BI Biz Swap
January 6, 2017
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…